Fighting obesity -- could it be as plain as dirt?

December 12, 2018

It costs the global economy an estimated US$2 trillion annually and has been dubbed a modern day health epidemic, but new research from the University of South Australia has unearthed a possible cure for obesity - and it is as plain as dirt!

Investigating how clay materials can improve drug delivery, UniSA researcher and PhD candidate, Tahnee Dening serendipitously discovered that the clay materials she was using had a unique ability to "soak up" fat droplets in the gut.

Dening says this accidental discovery could potentially be a cure for obesity.

"It's quite amazing really," Dening says. "I was investigating the capacity of specifically clay materials to improve the oral delivery and absorption of antipsychotic drugs, when I noticed that the clay particles weren't behaving as I'd expected.

"Instead of breaking down to release drugs, the clay materials were attracting fat droplets and literally soaking them up.

"Not only were the clay materials trapping the fats within their particle structure, but they were also preventing them from being absorbed by the body, ensuring that fat simply passed through the digestive system.

"It's this unique behaviour that immediately signalled we could be onto something significant - potentially a cure for obesity."

Being overweight can cause serious health conditions such as cardiovascular disease, type 2 diabetes, and some cancers.

According to the Australian Institute of Health and Welfare, obesity is increasing with almost two in three adults, and one in four children, now overweight or obese. And if its prevalence continues, we can expect nearly half the world's population to be overweight or obese by 2030.

With few effective drugs existing to counteract obesity, many companies are investing huge amounts to discover and develop alternative treatments for obesity.

Dening's research investigated the effects of montmorillonite - a natural clay material, purified from dirt and laponite - a synthetic clay - in rats fed a high-fat diet, comparing against placebo and a leading weight loss drug - orlistat. Monitoring over a two-week period, she found that while both the engineered clay formulations and orlistat delivered weight loss effects, the clay material outperformed the drug.

Dening says the findings offer new insights for obesity and weight-management, particularly when used in combination with the commercial drug, where there is potential for synergy.

"Our processed clay has an unusually high surface area which means it has a huge capacity to interact with and soak up digested fats and oils present in the foods we eat," Dening says.

"Orlistat on the other hand, is an enzyme inhibitor that blocks up to 30 per cent of dietary fat digestion and absorption, which leads to weight loss, but has unpleasant side effects such as stomach aches, bloating, flatulence and diarrhoea, which limits its use in weight loss as people choose to stop using it.

"What we're researching now is a synergistic approach with both the clay material and orlistat: the orlistat blocks the enzyme that digests fat molecules, and the clay particles trap these fats so they're excreted out of the body without causing gastrointestinal disturbances.

"We're essentially attacking fat digestion and absorption in two different ways and we hope this will lead to greater weight loss with fewer side effects."

UniSA Professor Clive Prestidge, and Dening's research supervisor, says the research has already captured the attention of potential investors.

"This is a significant discovery that provides new and exciting avenues for weight loss research which naturally attracts potential commercial partners," Prof Prestidge says.

"With a finding like this, people will naturally be keen to find out when they can try it. Given that the material is generally considered safe and is widely used in food and nutraceutical products, it is feasible that human clinical trials could start reasonably soon.

"Watch this space."
-end-
Contacts for interview: Tahnee Dening | mobile +61 437 682 106
email: tahnee.dening@mymail.unisa.edu.au

Professor Clive Prestidge +61 8 8302 2438 | mobile +61 422 801 222
email: Clive.Prestidge@unisa.edu.au

Media: Annabel Mansfield office (08) 8302 0351 | mobile: +61 417 717 504
email: Annabel.Mansfield@unisa.edu.au

University of South Australia

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.